Structural Heart Disease

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

These modifiable factors, among others, directly contribute to 88.7% of all IHD deaths in 2023.

Catch up on major trial results, groundbreaking guideline updates, and more.

O’Donoghue addresses the inherent limitations in the ACS guidelines, from the constant influx of further research to the ambiguity of certain treatment recommendations.

Although not statistically significant, the reduction represents a potential new pathway for treating patients with STEMI.

Pressman discusses his recent study highlighting the interplay between right ventricular end-diastolic volume and ejection fraction and the left ventricle’s health.

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Sorajja describes his team’s operation to implant the ring via a novel trans-septal system, effectively avoiding the need to stop the heart in MR treatment.

Catch up with major FDA decisions, critical conference news, and more.

Although the initial MACE composite outcome was not statistically significant, investigators saw follow-up MI risk reduced by >50%.

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

Researchers indicated an association between the index and 365-day mortality.

Anita Radhakrishnan, MD, leads a community screening effort to detect early heart disease in underserved populations in Pittsburgh.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.